Partial Response to First-Line Crizotinib in an Elderly Male Patient with ROS1 Translocation-Positive Lung Cancer
| Autor: | C. Engelke, Laura Kellner, Tobias Overbeck, Sara Hugo, Hans-Ulrich Schildhaus, Katja Schmitz, C. O. Sahlmann, Lorenz Trümper |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty NSCLC lcsh:RC254-282 03 medical and health sciences 0302 clinical medicine Partial response Internal medicine ROS1 medicine Adenocarcinoma of the lung Stage (cooking) Lung cancer Crizotinib business.industry Fluorescence in situ hybridization Precision medicine medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens 3. Good health Surgery 030104 developmental biology Male patient 030220 oncology & carcinogenesis ROS1 rearrangement Published online: March 2016 business medicine.drug |
| Zdroj: | Case Reports in Oncology, Vol 9, Iss 1, Pp 158-163 (2016) Case Reports in Oncology |
| ISSN: | 1662-6575 |
| Popis: | We report on a 90-year-old male patient with a ROS1-translocated adenocarcinoma of the lung who was treated with crizotinib as first-line therapy. After 11 months of treatment, we noticed complete metabolic response as measured by 18F-FDG-PET/CT scan and a partial response according to RECIST criteria. This patient indicates that ROS1 translocations are not restricted to young age, female gender and low stage. Furthermore, this case illustrates exemplarily that crizotinib therapy is effective and manageable even as first-line treatment in elderly patients with comorbidities. Based on our findings, we recommend to include elderly patients with advanced pulmonary adenocarcinomas in molecular screening approaches for ROS1 translocations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|